Add BrightSurf on Google Email

Taylor & Francis Group


Rabies treatment demonstrated as safe and effective for use in children in first pediatric trial

Researchers have demonstrated a new treatment called KEDRAB to be safe and effective for use in children with rabies, marking the first pediatric trial of any human rabies immunoglobulin currently available in the US. The study found no deaths or serious adverse events among participants, and most side effects were mild.

SourceTaylor & Francis Group·JournalHuman Vaccines & Immunotherapeutics·DateFeb 10, 2021

If healthy people are purposefully infected with COVID-19 for the sake of science, they should be paid

A multidisciplinary team of international experts recommends that healthy individuals participating in COVID-19 challenge trials should receive substantial payment. The study's findings reflect the importance of compensating research-related harms and minimizing risk to promote social value. The researchers' framework provides guidance...

SourceTaylor & Francis Group·JournalThe American Journal of Bioethics·DateFeb 5, 2021

'Alarming' COVID-19 study shows 80% of respondents report significant symptoms of depression

A national survey of over 1,000 young US adults finds alarming levels of loneliness associated with significant mental health issues, including depression, anxiety, substance use, and addiction. The study emphasizes the importance of providing access to psychological help and promoting social connectedness to address these problems.

SourceTaylor & Francis Group·JournalJournal of Psychoactive Drugs·DateNov 16, 2020